Zacks Investment Research cut shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) from a buy rating to a hold rating in a research report released on Tuesday morning.
According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
A number of other brokerages have also recently weighed in on AIMT. ValuEngine upgraded shares of Aimmune Therapeutics from a sell rating to a hold rating in a research note on Tuesday, June 13th. Piper Jaffray Companies reduced their price objective on shares of Aimmune Therapeutics to $38.00 in a research note on Wednesday, March 15th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $33.00.
Aimmune Therapeutics (NASDAQ:AIMT) traded up 1.42% during midday trading on Tuesday, hitting $21.50. 98,266 shares of the stock traded hands. The company has a 50-day moving average price of $18.53 and a 200-day moving average price of $19.95. The firm’s market cap is $1.08 billion. Aimmune Therapeutics has a 1-year low of $10.27 and a 1-year high of $27.31.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.05. Analysts predict that Aimmune Therapeutics will post ($2.66) EPS for the current year.
In related news, insider Mary M. Rozenman sold 45,060 shares of the business’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $20.85, for a total transaction of $939,501.00. Following the transaction, the insider now owns 30,129 shares of the company’s stock, valued at $628,189.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Eric Bjerkholt bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The shares were bought at an average cost of $19.84 per share, for a total transaction of $99,200.00. Following the transaction, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at approximately $99,200. The disclosure for this purchase can be found here. Insiders have sold 110,060 shares of company stock worth $2,253,865 in the last ninety days. 24.56% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock worth $130,000 after buying an additional 4,900 shares during the period. Daiwa SB Investments Ltd. bought a new position in shares of Aimmune Therapeutics during the first quarter worth about $132,000. American International Group Inc. raised its position in shares of Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after buying an additional 1,070 shares during the period. Nationwide Fund Advisors raised its position in shares of Aimmune Therapeutics by 23.7% in the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock worth $437,000 after buying an additional 3,851 shares during the period. Finally, Franklin Street Advisors Inc. NC bought a new position in shares of Aimmune Therapeutics during the first quarter worth about $450,000. 69.64% of the stock is currently owned by institutional investors and hedge funds.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.